INSULET CORPORATION (PODD) Spending and interest coverage
- R&D / revenue · 12 months: Value 11.33%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.55%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 11.33% | Research and development expense / revenue. Period ending 2026-06-30. $345.90M ÷ $3.05B × 100 ≈ 11.33% |
| Stock-based compensation / revenue · 12 months | 2.55% | Share-based compensation / revenue. Period ending 2026-06-30. $77.90M ÷ $3.05B × 100 ≈ 2.55% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 345.90M USD | Research and Development Expense |
| Revenue | 3.05B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 77.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 515.70M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $345.90M | $3.05B | $77.90M | $515.70M | (m) | 11.33% | 2.55% | (m) | (m) |
| 2026-03-31 | $331.20M | $2.90B | $65.80M | $507.10M | (m) | 11.42% | 2.27% | (m) | (m) |
| 2025-12-31 | $301.10M | $2.71B | $62.70M | $473.80M | (m) | 11.12% | 2.32% | (m) | (m) |
| 2025-09-30 | $270.80M | $2.52B | $62.40M | $436.80M | (m) | 10.74% | 2.47% | (m) | (m) |
| 2025-06-30 | $248.50M | $2.36B | $63.80M | $407.30M | (m) | 10.53% | 2.70% | (m) | (m) |
| 2025-03-31 | $229.00M | $2.20B | $73.30M | $340.80M | (m) | 10.41% | 3.33% | (m) | (m) |
| 2024-12-31 | $219.60M | $2.07B | $69.30M | $308.90M | (m) | 10.60% | 3.35% | (m) | (m) |
| 2024-09-30 | $201.00M | $1.98B | $61.90M | $306.00M | (m) | 10.13% | 3.12% | (m) | (m) |
| 2024-06-30 | $203.90M | $1.87B | $54.30M | $272.70M | (m) | 10.89% | 2.90% | (m) | (m) |
| 2024-03-31 | $205.10M | $1.88B | $50.40M | $249.20M | $37.50M | 10.92% | 2.68% | 6.65× | Reported |
| 2023-12-31 | $205.00M | $1.70B | $48.30M | $220.00M | $36.20M | 12.08% | 2.85% | 6.08× | Reported |
| 2023-09-30 | $212.50M | $1.47B | $46.90M | $137.10M | $38.70M | 14.46% | 3.19% | 3.54× | Reported |
| 2023-06-30 | $199.70M | $1.32B | $45.40M | $85.20M | $37.50M | 15.14% | 3.44% | 2.27× | Reported |
| 2023-03-31 | $187.20M | $1.07B | $43.50M | $27.40M | $36.90M | 17.50% | 4.07% | 0.74× | Reported |
| 2022-12-31 | $180.20M | $1.06B | $40.90M | $37.60M | $36.50M | 17.07% | 3.88% | 1.03× | Reported |
| 2022-09-30 | $172.50M | $1.10B | $38.30M | $63.80M | $42.40M | 15.68% | 3.48% | 1.50× | Reported |
| 2022-06-30 | $165.00M | $1.08B | $37.50M | $94.60M | $49.60M | 15.28% | 3.47% | 1.91× | Reported |
| 2022-03-31 | $162.50M | $1.10B | $35.30M | $147.60M | $57.10M | 14.82% | 3.22% | 2.58× | Reported |
| 2021-12-31 | $160.10M | $1.10B | $34.40M | $126.00M | $61.70M | 14.57% | 3.13% | 2.04× | Reported |
| 2021-09-30 | $156.60M | $1.04B | $41.40M | $69.00M | $59.40M | 15.10% | 3.99% | 1.16× | Reported |
| 2021-06-30 | $157.90M | $995.60M | $39.80M | $59.10M | $54.90M | 15.86% | 4.00% | 1.08× | Reported |
| 2021-03-31 | $152.00M | $958.70M | $36.60M | $60.30M | $50.10M | 15.85% | 3.82% | 1.20× | Reported |
| 2020-12-31 | $146.80M | $904.40M | $35.90M | $51.50M | $48.10M | 16.23% | 3.97% | 1.07× | Reported |
| 2020-09-30 | $141.40M | $867.70M | $28.30M | $76.90M | $46.20M | 16.30% | 3.26% | 1.66× | Reported |
| 2020-06-30 | $133.90M | $825.80M | $28.30M | $70.10M | $43.70M | 16.21% | 3.43% | 1.60× | Reported |
| 2020-03-31 | $132.70M | $776.60M | $30.80M | $50.20M | $39.60M | 17.09% | 3.97% | 1.27× | Reported |
| 2019-12-31 | $129.70M | $738.20M | $28.70M | $50.00M | $34.60M | 17.57% | 3.89% | 1.45× | Reported |
| 2019-09-30 | $122.20M | $693.71M | $27.02M | $48.10M | $30.48M | 17.62% | 3.89% | 1.58× | Reported |
| 2019-06-30 | $113.76M | $652.67M | $36.48M | $37.97M | $27.95M | 17.43% | 5.59% | 1.36× | Reported |
| 2019-03-31 | $100.29M | $599.80M | $35.12M | $34.69M | (m) | 16.72% | 5.86% | (m) | (m) |
| 2018-12-31 | $88.61M | $563.82M | $37.52M | $27.42M | $28.90M | 15.72% | 6.65% | 0.95× | Reported |
| 2018-09-30 | $78.87M | $529.44M | $39.59M | $10.42M | (m) | 14.90% | 7.48% | (m) | (m) |
| 2018-06-30 | $77.25M | $500.14M | $32.40M | $5.60M | (m) | 15.45% | 6.48% | (m) | (m) |
| 2018-03-31 | $76.86M | $485.63M | $33.00M | $-2.08M | (m) | 15.83% | 6.79% | (m) | (m) |
| 2017-12-31 | $74.45M | $463.77M | $31.94M | $-7.39M | $21.21M | 16.05% | 6.89% | -0.35× | Reported |
| 2017-09-30 | $71.70M | $436.82M | $30.32M | $-10.75M | (m) | 16.42% | 6.94% | (m) | (m) |
| 2017-06-30 | $65.30M | $409.92M | $27.49M | $-10.38M | (m) | 15.93% | 6.71% | (m) | (m) |
| 2017-03-31 | $60.22M | $387.49M | $25.47M | $-8.31M | (m) | 15.54% | 6.57% | (m) | (m) |
| 2016-12-31 | $55.71M | $366.99M | $23.62M | $-10.70M | (m) | 15.18% | 6.44% | (m) | (m) |
| 2016-09-30 | $52.57M | $347.21M | $22.18M | $-19.18M | (m) | 15.14% | 6.39% | (m) | (m) |
| 2016-06-30 | $48.87M | $384.07M | $20.33M | $-48.43M | (m) | 12.73% | 5.29% | (m) | (m) |
| 2016-03-31 | $47.99M | $357.29M | $19.14M | $-61.20M | (m) | 13.43% | 5.36% | (m) | (m) |
| 2015-12-31 | $43.21M | $324.23M | $19.18M | $-60.77M | (m) | 13.33% | 5.92% | (m) | (m) |
| 2015-09-30 | $37.60M | $296.67M | $18.12M | $-38.98M | (m) | 12.67% | 6.11% | (m) | (m) |
| 2015-06-30 | $34.72M | $284.35M | $23.57M | $-26.12M | (m) | 12.21% | 8.29% | (m) | (m) |
| 2015-03-31 | $29.33M | $280.77M | $23.46M | $-19.04M | (m) | 10.45% | 8.36% | (m) | (m) |
| 2014-12-31 | $27.90M | $288.72M | $22.52M | $-12.30M | (m) | 9.66% | 7.80% | (m) | (m) |
| 2014-09-30 | $27.04M | $284.69M | $21.13M | $-9.84M | (m) | 9.50% | 7.42% | (m) | (m) |
| 2014-06-30 | $25.65M | $270.81M | $14.42M | $-24.27M | (m) | 9.47% | 5.32% | (m) | (m) |
| 2014-03-31 | $24.15M | $258.89M | $14.05M | $-24.82M | (m) | 9.33% | 5.43% | (m) | (m) |
| 2013-12-31 | $21.77M | $247.08M | $12.68M | $-29.14M | (m) | 8.81% | 5.13% | (m) | (m) |
| 2013-09-30 | $21.19M | $236.38M | $12.22M | $-35.43M | (m) | 8.96% | 5.17% | (m) | (m) |
| 2013-06-30 | $21.98M | $230.03M | $11.61M | $-26.59M | (m) | 9.55% | 5.05% | (m) | (m) |
| 2013-03-31 | $23.32M | $220.97M | $10.31M | $-31.28M | (m) | 10.55% | 4.66% | (m) | (m) |
| 2012-12-31 | $24.36M | $211.37M | $9.92M | $-35.97M | (m) | 11.52% | 4.69% | (m) | (m) |
| 2012-09-30 | $24.32M | $200.73M | $9.63M | $-40.40M | (m) | 12.11% | 4.80% | (m) | (m) |
| 2012-06-30 | $22.39M | $190.57M | $9.07M | $-41.69M | (m) | 11.75% | 4.76% | (m) | (m) |
| 2012-03-31 | $22.71M | $171.75M | $8.38M | $-46.09M | (m) | 13.22% | 4.88% | (m) | (m) |
| 2011-12-31 | $21.86M | $152.25M | $7.73M | $-42.47M | (m) | 14.36% | 5.08% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $104.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $16.57M | $96.97M | $5.06M | $-38.63M | (m) | 17.08% | 5.22% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $13.23M | $66.03M | $4.20M | $-59.36M | (m) | 20.04% | 6.36% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |